Company news
Karyopharm Therapeutics Inc. news in 2026
Karyopharm Therapeutics Inc.'s news releases, calls and decks from 2026, newest first.
Karyopharm Announces FDA Acceptance of Supplemental New Drug Application for XPOVIO® (selinexor) Plus Ruxolitinib for the Treatment of Patients with Myelofibrosis
November 17, 2026
Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)
November 4, 2026
Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future
November 2, 2026
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 1, 2026
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
August 31, 2026
Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
August 13, 2026
Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026
August 10, 2026
Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
July 30, 2026
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
July 30, 2026
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026
June 3, 2026
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026
June 2, 2026
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 1, 2026
Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation
June 1, 2026
Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference
May 28, 2026
Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment
May 13, 2026
Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026
May 7, 2026
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction
March 23, 2026
Karyopharm Announces $30 Million Private Placement with RA Capital
March 23, 2026
Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
February 12, 2026
Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
February 5, 2026
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
February 3, 2026
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 2, 2026
Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026
January 12, 2026
Calls in 2026
Decks in 2026
- Q2 2026 Earnings Presentation
Earnings · 40 slides · Aug 13, 2026
- Investor Presentation (May 2026)
Investor deck · 59 slides · May 2026
- Technical Presentation (March 2026)
Technical · 23 slides · Mar 24, 2026
- Q4 2025 Earnings Presentation
Earnings · 35 slides · Feb 12, 2026